OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

February 13th 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

Dr. Cho Discusses Role of Bispecific Agents in Myeloma

February 12th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.

Dr. Grigg Discusses CABOSUN Trial in mRCC

February 12th 2019

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the design and results of the CABOSUN trial in metastatic renal cell carcinoma.

Dr. Burris on Molecular Profiling in Breast Cancer

February 12th 2019

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

Dr. Dorff on Sequencing in Metastatic Castration-Resistant Prostate Cancer

February 12th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses sequencing in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hamilton on Emerging Therapies in HER2+ Breast Cancer

February 12th 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

Dr. George Discusses Ongoing Trials in Soft Tissue Sarcoma

February 12th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

Dr. Subramanian on the Future of Immunotherapy in NSCLC

February 9th 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discusses the future of immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Rule on Treatment Approaches for Patients With p53-Mutated MCL

February 9th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses treatment approaches for patients with p53-mutated mantle cell lymphoma (MCL).

Dr. Karam on the Use of Laparoscopy in Advanced Ovarian Cancer

February 9th 2019

Amer Karam, MD, associate clinical professor of Gynecologic Oncology at Stanford Hospital and director of Robotic Surgery and Outreach in the Division of Gynecologic Oncology at Stanford Medicine, discusses the use of laparoscopy in advanced ovarian cancer.

Dr. Lee on Differences Between HIPEC and PIPAC in mCRC

February 9th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.

Dr. Holstein Discusses Mechanism of bb21217 in Myeloma

February 9th 2019

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the mechanism of action for bb21217 in the treatment of patients with myeloma.

Dr. Rayford on Improving Stratification of Patients With Prostate Cancer

February 9th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses ways to improve stratification of patients with prostate cancer.

Dr. Holstein on Sequencing Strategies in Myeloma

February 8th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska, discusses considerations for determining on optimal treatment sequence for patients with myeloma.

Dr. Figlin Discusses Future of RCC Treatment

February 8th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.

Dr. Mody Highlights Treatment Advances in HCC

February 8th 2019

Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.

Dr. Arora on the Use of Venetoclax in CLL

February 8th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Drilon Discusses the Adoption of NGS in Lung Cancer

February 8th 2019

Alexander E. Drilon, MD, medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discusses the adoption of next-generation sequencing (NGS) in lung cancer.

Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

February 8th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer

February 7th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.